Skip to main content

Table 3 Reasons for antiretroviral modification among HIV patients on HAART

From: Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia

 

1

2

3

4

5

6

Total

Drug out of stock

0(0.00)

0(0.00)

3(5.56)

0 (0.00)

0 (0.00)

0(0.00)

3(0.48)

Hepatitis

0(0.00)

0(0.00)

1 (1.85)

0 (0.00)

0(0.00)

0(0.00)

1(0.16)

New TB

68(16.35)

3(3.00)

15 (27.78)

0 (0.00)

1(5.88)

1(25.00)

88(14.31)

Phaseout

106(25.48)

18 (18.00)

0(0.00)

0 (0.00)

0(0.00)

0(0.00)

124(20.16)

Pregnancy

1(2.40)

6 (6.00)

0 (0.00)

5 (20.83)

11(64.70)

1(25.00)

24(3.9)

Toxicity/side effect

198(47.59)

56(56.00)

29 (53.70)

13 (54.17)

3(17.65)

2(50.00)

301(48.94)

Treatment failure

2(4.1)

1 (1.00)

1 (1.85)

0 (0.00)

0 (0.00)

0(0.00)

4(0.65)

unknown

41 (9.86)

16 (16.00)

5 (9.26)

6 (25.00)

2 (11.76)

0(0.00)

70(11.38)

Total change

416

100

54

24

17

4

615

  1. Note: 1: d4T + 3TC + NVP, 2: d4T + 3TC + EFV, 3: AZT + 3TC + NVP, 4: AZT + 3TC + EFV, 5: TDF + 3TC + EFV, and 6: TDF + 3TC + NVP